Connect Biopharma Holdings Limited
AI Valuation
AI-generated fair value estimate for this company.
AI Fair Value
$0.49
Market Price
$0.93
Overvalued By
89.2%
Method: Net cash NAV: $31.49M cash & short-term investments (6/30/26) minus $0.6M total debt = $30.89M net cash, divided by 62.97M shares outstanding.
Reasoning: Connect Biopharma is pre-revenue with its lead asset rademikibart only in Phase 2 (binary trial-outcome risk, no disclosed peak-sales estimate reliable enough to rNPV), and burn (~$15-17M/quarter) is consuming cash quickly, so net cash is the most grounded, data-backed value rather than a speculative pipeline DCF.